• defects in, or deficiency of, complement components, including factor H, factor D or properdin deficiency
  • current or future treatment with eculizumab (a monoclonal antibody directed against complement component C5)
  • functional or anatomical asplenia, including sickle cell disease or other haemoglobinopathies, and congenital or acquired asplenia
  • HIV, regardless of disease stage or CD4+ cell count
  • haematopoietic stem cell transplant
Last updated: 
5 June 2018
Last reviewed: 
5 June 2018